Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs. JIMKI 2025, 10. https://doi.org/10.53366/jimki.vi.961.